Design and rationale of a randomized clinical trial assessing the effect of inclisiran on atherosclerotic plaque in individuals without previous cardiovascular event and without flow- limiting lesions identified in an in-hospital screening – The VICTORION-PLAQUE primary prevention trial
Related Posts
Sheng Q, Brownell NK, Hsu JJ, Chang DS, Fonarow GC, Ziaeian B. Dashboard-Directed Intervention to Improve Guideline-Directed Heart Failure Therapy for Veterans. JACC Adv. 2026[...]
Miyahira A, Czernin J. An Immunologist's Path Toward Advancing the Scientific Mission of the Prostate Cancer Foundation: Andrea Miyahira Talks with Johannes Czernin About the[...]
Shoji S, Ikeaba U, Fonarow GC, Selvaraj S, Lewsey SC, Pandey A, Khouri MG, Alhanti B, McDermott JJ, Wright J, Vaduganathan M, Greene SJ. Clinical[...]